{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["18(2)"],"submitter":["Aghemo A"],"funding":["AbbVie"],"pubmed_abstract":["<h4>Introduction</h4>Glecaprevir/pibrentasvir (G/P) has demonstrated high rates (>95%) of sustained virologic response at posttreatment Week 12 (SVR12) in treatment-naïve (TN) patients with hepatitis C virus (HCV) infection and compensated cirrhosis (CC). Here, in a key real-world subset of TN Italian patients with CC, we evaluated the effectiveness and safety of 8-week G/P treatment, including subgroups of interest such as those with genotype 3 (GT3) infection, elderly patients, and those with more advanced liver disease.<h4>Methods</h4>Subanalysis of Italian patients enrolled in the CREST study. The full analysis set (FAS) included all patients enrolled in the study; the modified analysis set (MAS) excluded patients who discontinued G/P for nonvirologic failure or who had missing SVR12 r"],"journal":["PloS one"],"pagination":["e0280165"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9894491"],"repository":["biostudies-literature"],"pubmed_title":["Safety and effectiveness of 8 weeks of Glecaprevir/Pibrentasvir in challenging HCV patients: Italian data from the CREST study."],"pmcid":["PMC9894491"],"pubmed_authors":["D'Ambrosio R","Bhagat A","Gasbarrini A","Gualberti G","Villa E","Gallinaro V","Merolla RCD","Aghemo A","Persico M","Andreoni M"],"additional_accession":[]},"is_claimable":false,"name":"Safety and effectiveness of 8 weeks of Glecaprevir/Pibrentasvir in challenging HCV patients: Italian data from the CREST study.","description":"<h4>Introduction</h4>Glecaprevir/pibrentasvir (G/P) has demonstrated high rates (>95%) of sustained virologic response at posttreatment Week 12 (SVR12) in treatment-naïve (TN) patients with hepatitis C virus (HCV) infection and compensated cirrhosis (CC). Here, in a key real-world subset of TN Italian patients with CC, we evaluated the effectiveness and safety of 8-week G/P treatment, including subgroups of interest such as those with genotype 3 (GT3) infection, elderly patients, and those with more advanced liver disease.<h4>Methods</h4>Subanalysis of Italian patients enrolled in the CREST study. The full analysis set (FAS) included all patients enrolled in the study; the modified analysis set (MAS) excluded patients who discontinued G/P for nonvirologic failure or who had missing SVR12 r","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023","modification":"2026-03-31T10:39:57.067Z","creation":"2025-04-06T14:06:10.708Z"},"accession":"S-EPMC9894491","cross_references":{"pubmed":["36730135"],"doi":["10.1371/journal.pone.0280165"]}}